Thursday 16 October, 2025
Introduction: A population pharmacokinetic (PopPK) model was developed to characterize mecillinam (MEC) pharmacokinetics (PK) and urine exposure after intravenous (IV)…
Read morePoster: Drug/Disease Modelling - Infection
Integration of the LeiCNS-PK3.0 PBPK framework and multiscale data to select anti-COVID19 drugs with favorable brain pharmacokinetics
Thursday 16 October, 2025
ObjectivesIncreasing concerns about the CNS involvement in COVID-19 have been raised by the associated neurological manifestations [1–3]. SARS-CoV-2 has also…
Read moreNon-linear binding model of total daptomycin in patients with normal and impaired renal function
Thursday 16 October, 2025
Introduction: Daptomycin is authorized for the treatment of complicated skin and soft tissue infections (IPPBc), right-sided infective endocarditis (EID) due…
Read moreLassa viral dynamics in macaques treated with favipiravir or ribavirin
Thursday 16 October, 2025
Objectives: Lassa fever is a potentially lethal/disabling hemorrhagic fever, endemic in West Africa, caused by Lassa virus (LASV), that afflicts…
Read moreModelling SARS-CoV-2 viral dynamics in hospitalized patients: implications for therapeutic evaluation
Thursday 16 October, 2025
Context: In the last two decades, modelling has largely contributed to unravel the determinants of host/pathogen interaction of viral infections,…
Read moreVancomycin clearance in obese adults is not predictive of clearance in obese adolescents
Thursday 16 October, 2025
Objectives: Contradictory pharmacokinetic (PK) results have been observed between obese adults and obese adolescents for hepatically cleared drugs, with propofol…
Read moreA population pharmacokinetic analysis to evaluate the impact of body weight, renal function, and patient status on vancomycin pharmacokinetics
Thursday 16 October, 2025
Objectives: Vancomycin is commonly used to treat severe Gram-positive bacterial infections. Due to its highly variable PK and narrow therapeutic window,…
Read morePrediction of C-reactive protein dynamics during meropenem treatment in very-low-birth-weight neonates with late-onset sepsis or pneumonia
Thursday 16 October, 2025
Objectives. Sepsis is major cause of mortality in neonates. Blood cultures are often negative, antibiotic (AB) dosing cannot be always…
Read moreDetermination of risk factors for time to culture conversion in tuberculosis patients receiving novel regimen
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) is the leading cause of death from a single infectious agent worldwide1. The fact that the lengthy 6-month…
Read moreA QSP model to inform dose decision and fast track candidate lead in mRNA vaccines development
Thursday 16 October, 2025
Introduction: Over the past two years mRNA vaccine platforms have proven to be a formidable tool to quickly develop and deploy…
Read more